miR-221 has been reported to be dysregulated in a variety of tumor types and has previously been shown to be involved in suppression of ERα expression in luminal breast cancer cells and EMT transition in basal-like breast cancers [23]–[26], [29], [30], [39]. Here, ESR1 is linked to breast carcinoma.